Dynogen Pharmaceuticals
Boston
About Dynogen Pharmaceuticals
Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $63.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2004)
- Phone: +1 617-357-8000
Industries & Categories
Clinical Trials, Life Science, Medical
Canonical: https://fsome.com/organization/dynogen-pharmaceuticals-988181 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.